论文部分内容阅读
目的 :分析老年食管癌患者接受放疗联合替吉奥同期化疗的疗效、不良反应和预后。方法 :2011年7月—2014年7月,46例接受放疗联合替吉奥同期化疗的老年食管癌患者(年龄≥70岁)符合病例入组标准。观察同期放化疗的疗效和不良反应。采用Kaplan-Meier法进行生存分析。结果 :所有46例患者均完成放疗联合替吉奥同期化疗。全组患者的食管内镜下原发肿瘤病灶完全缓解率为60.9%(28/46),总有效率(完全缓解+部分缓解+疾病稳定)为93.5%(43/46);按照实体瘤疗效评价标准,全组患者的原发肿瘤病灶完全缓解率为41.3%(19/46),客观缓解率为93.5%(43/46)。46例患者的中位生存期为23.0个月(95%可信区间:21.1~24.9个月),中位无进展生存期为18.0个月(95%可信区间:14.9~21.1),1年和2年生存率分别为88.3%和45.3%。结论 :老年食管癌患者接受放疗联合替吉奥同期化疗的近期疗效和耐受性均较好,不良反应轻微。替吉奥单药口服可作为局部进展期老年食管癌患者同期放化疗的治疗选择。
OBJECTIVE: To analyze the efficacy, side effects and prognosis of elderly patients with esophageal cancer treated with radiotherapy combined with tirofiban. Methods: From July 2011 to July 2014, 46 elderly patients with esophageal cancer who underwent radiotherapy combined with tirofiban for chemotherapy (age ≥70 years) met the inclusion criteria. Observed the same period of radiotherapy and chemotherapy efficacy and adverse reactions. Survival analysis was performed using Kaplan-Meier method. RESULTS: All 46 patients completed radiotherapy combined with tegaserod chemotherapy. The complete remission rate of esophageal endoscopic primary tumor lesions was 60.9% (28/46) in all patients, and the total effective rate (complete remission + partial remission + stable disease) was 93.5% (43/46). According to the solid tumor efficacy Evaluation criteria, the complete group of patients with primary tumor lesions complete remission rate was 41.3% (19/46), the objective response rate was 93.5% (43/46). The 46 patients had a median survival of 23.0 months (95% confidence interval: 21.1-24.9 months), median progression-free survival of 18.0 months (95% confidence interval: 14.9-21.1), and 1 year And 2-year survival rates were 88.3% and 45.3% respectively. Conclusion: Elderly patients with esophageal cancer receiving radiotherapy combined with tirofiban for the same period of time the efficacy and tolerability of chemotherapy are good, minor adverse reactions. As a single agent orally for the treatment of locally advanced esophageal cancer in patients with concurrent chemotherapy treatment options.